Novo Nordisk A/S
Ro to offer lower-price vials of weight loss drug Zepbound by teaming up with Eli Lilly
Patients will be able to access Zepbound single-dose vials at Ro Coutesy: Ro Direct-to-consumer health-care startup Ro on Wednesday said its platform will now offer more affordable single-dose vials of the weight loss drug Zepbound through a new partnership with Eli Lilly, which aims to streamline access to the popular treatment. Ro said it will […]
Read More
The weight-loss drug boom has become one of the internet’s biggest scams
A production line of Wegovy injection pens for the Asian market at the Novo Nordisk A/S pharmaceutical manufacturing facility in Hillerod, Denmark, on Wednesday, Nov. 27, 2024. Bloomberg | Bloomberg | Getty Images One interpretation of the law of supply and demand is that when demand outstrips supply, scammers get busy. That’s certainly the case […]
Read More
Healthy Returns: Wall Street mulls over Amgen’s weight loss drug data
The Amgen logo is displayed outside Amgen headquarters in Thousand Oaks, California, on May 17, 2023. Mario Tama | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Wall Street is chewing over critical […]
Read More
Prescription fills for weight loss drugs Zepbound and Wegovy more than doubled in 2024, GoodRx says
A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, made by Novo Nordisk. Reuters Prescription fills for blockbuster weight loss drugs in the U.S. more than doubled in 2024, even with limited insurance coverage and high out-of-pocket costs for the treatments, according to data released Thursday […]
Read More
Eli Lilly’s obesity drug beats rival in head-to-head trial — where Cramer sees shares going next
New trial data has cemented Club holding Eli Lilly ‘s pole position in the highly competitive obesity drug race. The news Eli Lilly’s obesity drug Zepbound bested its main rival Wegovy — made by Denmark’s Novo Nordisk — in the first head-to-head trial comparing the fast-growing weight loss treatments. Patients on Zepound lost an average […]
Read More
Eli Lilly’s Zepbound causes greater weight loss than Novo Nordisk’s Wegovy in head-to-head trial
A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, made by Novo Nordisk. Reuters Eli Lilly on Wednesday said its obesity drug Zepbound led to more weight loss than its main rival, Novo Nordisk‘s Wegovy, in the first head-to-head clinical trial on the weekly injections. The […]
Read More
Stocks making the biggest moves midday: Kohl’s, Best Buy, Zoom Communications, Stellantis and more
Check out the companies making headlines in midday trading. Kohl’s – Shares tumbled 18% after the retailer cut its sales outlook amid an uncertain holiday backdrop . The latest quarter’s earnings and sales fell short of Wall Street analysts’ estimates, and the CEO will step down in January. Amgen — The biotech fell more than […]
Read More
Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau
The Amgen logo is displayed outside Amgen headquarters in Thousand Oaks, California, on May 17, 2023. Mario Tama | Getty Images Amgen on Tuesday said its experimental weight loss injection helped patients with obesity lose up to 20% of their weight on average after a year in a critical mid-stage trial, as the company races […]
Read More
Biden proposes Medicare and Medicaid cover costly weight-loss drugs for millions of obese Americans
Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. Hollie Adams | Reuters Millions of Americans with obesity would be eligible to have popular weight-loss drugs like Wegovy or Ozempic covered by Medicare or Medicaid under a new rule the Biden administration proposed Tuesday […]
Read More
Barclays says these global stocks are ripe for share buybacks — and analysts give one 45% upside
European equity markets might look “gloomy” right now, but Barclays noted that one investment strategy has delivered “solid outperformance” over recent months. “Buyback strategies remain a bright spot for Europe, with strong volumes and returns. Amid a gloomy equity market, our buyback announcement basket (BCEUBUYB) has outperformed by 4.6% since Oct,” the investment bank’s strategists […]
Read More